Sunday, September 24, 2017
Minimize

CONTACTS

Phone: (706) 721-3410

Email: jshe@augusta.edu

Room: CA4126 

Address:

Medical College of Georgia,
CBGM, 1120 15th Street,
CA4126,
Augusta, GA 30912
GRU Faculty Page


EDUCATION


Post-doc., Immunogenetics,
University of Florida
 
Ph.D., Molecular Genetics,
University of Montpellier, France
 
M.S., Fish Biology,
National School of Agriculture, France
 
B.S., Fish Biology,
Agricultural College of Central China
Minimize
JIN-XIONG SHE: 
       DIRECTOR CBGM, Bradley Turner Eminent Scholar Chair in Genomic Medicine

Minimize
General Information
RESEARCH INTEREST 

Dr. She's research focuses on the elucidation of disease mechanisms, biomarker discovery and drug development for autoimmune diseases, transplantation, diabetes and its complications and cancer.  The experimental approaches include genetics, genomics, proteomics, high throughput/high content drug screening, and bioinformatics. The ultimate goals of the research programs are to develop knowledge and strategies for predictive, preventive, personalized and participatory medicine.

Minimize
RESEARCH PROJECTS
High Throughput Drug Screening 
This programs seeks to identify drug candidates through high throughput/high content screening of large libraries of drug-like chemical compound libraries.  Drug candidates are further developed for clinical use and studies of disease mechanisms.  We are currently developing drugs against cancer, transplant rejection, inflammation and autoimmune diseases.
  
Cancer Biomarkers 
Using high throughput proteomic tools, we have recently identified a number of serum biomarkers for the early detection and diagnosis of ovarian cancer.  Current efforst are devoted to the validation of these biomarker candidates.  Similar strategies are also being applied to other types of cancers.

Mouse Genetics 
Using mouse models of various human conditions, this program seeks to identify genes responsible for various diseases including type 1 diabetes, pancreatitis and lymphoma.  Congenic, transgenic and knockout technologies combined with high throughput gene expression arrays and proteomics tools are used to dissect the contribution of various genes to the complex disease phenotypes.

Human Genetics 
Using various genetic mapping tools and functional studies, this program seeks to understand the genetic basis of human complex diseases including type 1 diabetes and other autoimmune diseases.   

Functional Genomics 

High throughput genomic technologies are used to investigate the normal function of the immune system as well as its malfunction in autoimmune diseases.  These tools are also applied to human patient populations to identify biomarkers for various human diseases including type 1 diabetes, diabetic complications and cancer.   

Proteomics 
This program is developing various proteomic tools for the identification and quantification of complex proteomes.  Proteomic platforms include Luminex beads, 2D PAGE, 3D proteomics using 2D HPLC and various mass spectrometry techniques (LTQ, MALDI-TOF/TOF and SELDI).  These techniques are used to understand the cellular functions of various systems as well as biomarker discovery for human diseases (clinical proteomics).   

TEDDY: The Environmental Determinants of Diabetes in the Young 
This is a clinical center of the international consortium, TEDDY (The environmental determinants of diabetes in the young), which aims at identifying the environmental triggers for type 1 diabetes in genetically susceptible individuals.  TEDDY screens over 400,000 newborns in six international centers and identifies 8,000 high risk babies for long term (15 years) follow-up studies.   

TEDDY RNA Laboratory 
The TEDDY RNA Laboratory is a high throughput facility to purify large numbers of RNA and DNA samples collected by the TEDDY study, which aims at identifying the environmental triggers for type 1 diabetes in genetically susceptible children.   

PANDA: Prediction and Prevention of Type 1 Diabetes 
The PANDA (prospective assessment in newborns of diabetes autoimmunity) was established in 1997 and seeks to screen newborns and young relatives of type 1 diabetes patients using genetic markers.  The high risk subjects are monitored prospectively and at regular time intervals.  Samples collected from these cohort are used to investigate the immunopathogenesis of type 1 diabetes using a variety of approaches including genetics, genomics, proteomics and cellular immunology tools. High risk subjects may also be enrolled for clinical trials aimed at preventing diabetes or its complications.

Minimize
PUBLICATIONS
Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes.
Purohit S, Podolsky R, Collins C, Zheng W, Schatz D, Muir A, Hopkins D, Huang YH, She JX
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta, GA 30912, USA. spurohit@mail.mcg.edu
Proteomic analysis of SUMO4 substrates in HEK293 cells under serum starvation-induced stress.
Guo D, Han J, Adam BL, Colburn NH, Wang MH, Dong Z, Eizirik DL, She JX, Wang CY
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, GA 30912, USA.
Molecular pathways altered by insulin b9-23 immunization.
Eckenrode SE, Ruan QG, Collins CD, Yang P, McIndoe RA, Muir A, She JX
CBGM, Medical College of Georgia, 1120 15th Street, CA-4124, Augusta, GA 30912, USA.
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes.
Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, Georgia 30912, USA.
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes.
Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko T, Atkinson M, Pozzilli P, Zeidler A, Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, Bach JF, Rotter JI, She JX, Wang CY
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, CA4098, Augusta, Georgia 30912, USA.
Minimize
STUDENTS/STAFF
  Name Role Email Telephone
Bo Chen, PhD Assistant Professor, Cancer drug development bchen@augusta.edu 706-721-3403
Robert Schleifer  Graduate student rschleifer@augusta.edu 706-721-3403
Rui Mao, PhD Postdoctoral Fellow, Drug Screening rmao@augusta.edu 706-721-3403
Sharad Purohit Assistant Professor, Lab Manager, Proteomics spurohit@augusta.edu 706-721-3403
Brandon Gramazio  Graduate student bgramazio@augusta.edu 706-721-3403
  Paul Tran Graduate student ptran@augusta.edu 706-721-3403 
  Lynn Tran Graduate student lytran@augusta.edu 706-721-3403 
  Stephanie Christianson  Graduate student  schristianson@augusta.edu 706-721-3403
  Haitao Liu, MD Postdoctoral Fellow hailiu@augusta.edu 706-721-3403 
  Shuchun Li, PhD Postdoctoral Fellow shuli@augusta.edu 706-721-3403


Home   |   Faculty and Staff
Copyright 2017 Georgia Regents University